Fundraising Fox

Delve Bio

Founded 2022 · 43 employees on LinkedIn · 3 known investors

Find your way into Delve Bio

Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Delve Bio was founded in 2022 by Dr. Joseph DeRisi.

DJ
Dr. Joseph DeRisiFounder

Investors · 3

GV (Google Ventures)Mountain View · $250K – $50M
Perceptive Xontogeny VenturereportedNew York
Section 32reportedPalo Alto

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Delve Bio | Company Profile - Revenue, Headcount, Tech Stack, Contactsbitscale.ai · Mar 2026Delve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS) - BioSpacebiospace.com · Oct 2024Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infectionsbusinesswire.com · Apr 2024Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis - Xontogenyxontogeny.com · Jun 2023Delve Bio Raises $35M in Series A Financing to Develop Metagenomic Sequencing Diagnostics | GenomeWebgenomeweb.com · Jun 2023

Frequently asked questions

What does Delve Bio do?
Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.
Who founded Delve Bio?
Delve Bio was founded by Dr. Joseph DeRisi in 2022.
Who are Delve Bio's investors?
Delve Bio's investors include GV (Google Ventures), Perceptive Xontogeny Venture, Section 32.